LAUSR

Valproate Teratogenicity: A Moving Target.

Sign Up to like & get
recommendations!
1 Published in 2022 at "Obstetrics and gynecology"

DOI: 10.1097/aog.0000000000004893

Abstract: Within several years after receiving U.S. Food and Drug Administration (FDA) approval in the late 1970s, valproate was shown to increase the risk for major congenital malformations and learning disabilities in the offspring of women… read more here.

Keywords: drug; moving target; valproate teratogenicity; teratogenicity moving ... See more keywords